Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent
Biotech execs don’t quite know what to make of the new FDA chief. There’s been plenty of head-shaking about the controversial provocateur he named to run CBER. Robert F. Kennedy Jr. at ...
Biotech execs don’t quite know what to make of the new FDA chief. There’s been plenty of head-shaking about the controversial provocateur he named to run CBER. Robert F. Kennedy Jr. at ...
